Induction Treatment in Transplant-eligible Multiple Myeloma :: UTM Library Massive Scholar Tracking

Bibliographic Details
Main Authors:	J. Quinn, S. Glavey, C. Comerford, P. Murphy
Format:	Article
Language:	English
Published:	Wiley 2021-05-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000560

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
by: C. Duane, et al.
Published: (2022-06-01)

Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Olga Lytvynova, et al.
Published: (2024-09-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Paul Richardson, et al.
Published: (2010-05-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Anuj Mahindra, et al.
Published: (2010-05-01)

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers
by: Mohamad Mohty, et al.
Published: (2014-03-01)

PB1993: MULTIPLE MYELOMA BRAZILIAN REGISTER- HOW ABOUT THE TRANSPLANT ELIGIBLE PATIENTS?
by: E. Crusoe, et al.
Published: (2022-06-01)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
by: Elena Zamagni, et al.
Published: (2020-12-01)

PB1992: HISPANIC ETHNICITY AS A STRONG PREDICTOR OF POOR RESPONSE TO INDUCTION THERAPY AND ASCT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: I. Chineke, et al.
Published: (2022-06-01)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
by: Shah, V, et al.
Published: (2020)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
by: Hedwig M. Blommestein, et al.
Published: (2019-05-01)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
by: Graham H Jackson, et al.
Published: (2021-01-01)

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
by: Natalie S. Callander, et al.
Published: (2024-04-01)

EVALUATION OF DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (D-VRD) INDUCTION FOLLOWED BY DARATUMUMAB AND LENALIDOMIDE (DR) MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN BRAZIL
by: JTD Souto-Filho, et al.
Published: (2024-10-01)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
by: Ruth Wester, et al.
Published: (2019-11-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01)

Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients
by: Enrica Borsi, et al.
Published: (2024-04-01)

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients
by: Aikaterini Panopoulou, et al.
Published: (2023-02-01)

P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Tereza Popková, et al.
Published: (2023-08-01)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
by: Ruth Wester, et al.
Published: (2020-08-01)

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
by: Ajai Chari, et al.
Published: (2024-07-01)

Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma
by: Lyndsey Flanagan, et al.
Published: (2024-03-01)

PB2109: PROGNOSTIC VALUE OF MYC STRUCTURAL VARIATIONS IDENTIFIED BY FISH IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Ines Dos Santos Marques, et al.
Published: (2023-08-01)

Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients
by: Ahmed Kotb Abdrabou, et al.
Published: (2024-03-01)

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma
by: Elias K. Mai, et al.
Published: (2015-06-01)

Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism
by: Catherine Duane, et al.
Published: (2025-03-01)

Identification of clinical‐biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation
by: Lorenzo Cillo, et al.
Published: (2024-08-01)

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant eligible newly diagnosed multiple myeloma: a multicentre real-world experience.
by: Marika Porrazzo, et al.
Published: (2024-10-01)

Hypersialylation and multiple myeloma
by: Michael O’Dwyer, et al.
Published: (2024-02-01)

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study
by: Cyrille Hulin, et al.
Published: (2021-03-01)

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA
by: P. Malandrakis, et al.
Published: (2023-05-01)

P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
by: K. Groen, et al.
Published: (2022-06-01)

PB1987: DOMESTIC OPPORTUNITY IN HEAVILY PRETREATED MULTIPLE MYELOMA NOT ELIGIBLE TO HOSPITAL-BASED TREATMENT: ROLE OF POMALIDOMIDE-DEXAMETHASONE
by: C. Cerchione, et al.
Published: (2022-06-01)

Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study
by: Françoise Kraeber-Bodéré, et al.
Published: (2022-10-01)

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04
by: C. Touzeau, et al.
Published: (2022-06-01)

Daratumumab‐based induction and autologous transplantation in concomitant multiple myeloma and chronic myeloid leukemia
by: Carmine Liberatore, et al.
Published: (2023-11-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01)

Improved overall survival of transplant eligible newly diagnosed multiple myeloma patients in a Chilean public center. How did we achieve it?
by: Camila Peña, et al.
Published: (2024-10-01)

REAL-WORLD DATA ON THE DARATUMUMAB PLUS BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY LENALIDOMIDE MAINTENANCE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
by: EQ Crusoe, et al.
Published: (2024-10-01)

Minimal residual disease assessment in transplant-eligible patients with multiple myeloma: real-world applications of multiparametric flow cytometry-DURAClone (CAREMM-2104)
by: Ari Ahn, et al.
Published: (2024-07-01)

P24 HIGH-DOSE CYCLOPHOSPHAMIDE 4 GR/M2 AND STEM-CELL COLLECTION AFTER DARATUMUMAB-BASED QUADRUPLET INDUCTION IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS: A SINGLE-CENTER EXPERIENCE
by: C. Liberatore, et al.
Published: (2023-05-01)

Induction Treatment in Transplant-eligible Multiple Myeloma

Similar Items

Similar Items